The Napo Pharmaceuticals case study provides students with an example of a biotech company that has pursued a triple bottom line of people, planet, and profit while making life-saving drugs like crofelemer to deal with diarrhea in adult HIV/AIDS patients and potentially diarrhea for children and other neglected diseases around the world. The case study focuses on CEO and founder, Lisa Contes challenging road to the point where she and her distribution partners achieved FDA approval for the drug. The case study outlines the issues such mission-oriented biotech companies faced in the more typical profit-oriented world of biotech
Notes
Originally published in Raube, K. (2014). Napo Pharmaceuticals: Triple Bottom Line of People, Planet, and Profits (A). The Berkeley-Haas Case Series. University of California, Berkeley. Haas School of Business
